{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:08:41Z","timestamp":1788970121982,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"DOI":"10.1038\/s41575-026-01259-9","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:18:05Z","timestamp":1788967085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond inflammation: the residual burden as the next target in inflammatory bowel disease"],"prefix":"10.1038","author":[{"given":"Brigida","family":"Barberio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-4359","authenticated-orcid":false,"given":"Alexander C.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1572-0118","authenticated-orcid":false,"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3187-2894","authenticated-orcid":false,"given":"Edoardo V.","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"1259_CR1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner, D. et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160, 1570\u20131583 (2021).","journal-title":"Gastroenterology"},{"key":"1259_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/ibd\/izae119","volume":"31","author":"J Burisch","year":"2025","unstructured":"Burisch, J. et al. Residual disease burden among European patients with inflammatory bowel disease: a real-world survey. Inflamm. Bowel Dis. 31, 411\u2013424 (2025).","journal-title":"Inflamm. Bowel Dis."},{"key":"1259_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S2468-1253(20)30300-9","volume":"5","author":"KM Fairbrass","year":"2020","unstructured":"Fairbrass, K. M., Costantino, S. J., Gracie, D. J. & Ford, A. C. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5, 1053\u20131062 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1259_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S2468-1253(21)00014-5","volume":"6","author":"B Barberio","year":"2021","unstructured":"Barberio, B., Zamani, M., Black, C. J., Savarino, E. V. & Ford, A. C. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 6, 359\u2013370 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1259_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae133","volume":"19","author":"OM Nardone","year":"2025","unstructured":"Nardone, O. M. et al. Prevalence of sexual dysfunction in inflammatory bowel disease: systematic review and meta-analysis. J. Crohn\u2019s Colitis 19, jjae133 (2025).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"1259_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14713","volume":"36","author":"B Barberio","year":"2024","unstructured":"Barberio, B., Fairbrass, K. M., Gracie, D. J. & Ford, A. C. Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 12 months of longitudinal follow-up. Neurogastroenterol. Motil. 36, e14713 (2024).","journal-title":"Neurogastroenterol. Motil."},{"key":"1259_CR7","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.dld.2025.05.006","volume":"57","author":"EV Savarino","year":"2025","unstructured":"Savarino, E. V. et al. IBD impact on quality of life and perception of disease activity in Italian patients and physicians: an IBD-PODCAST study sub analysis. Dig. Liver Dis. 57, 1761\u20131771 (2025).","journal-title":"Dig. Liver Dis."},{"key":"1259_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1053\/j.gastro.2026.04.008","volume":"171","author":"C Ma","year":"2026","unstructured":"Ma, C. et al. Recommendations for the evaluation and management of inflammatory bowel disease with irritable bowel syndrome-like symptoms: a joint Rome Foundation and International Organization for the Study of IBD (IOIBD) consensus. Gastroenterology 171, 504\u2013520 (2026).","journal-title":"Gastroenterology"},{"key":"1259_CR9","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1053\/j.gastro.2020.10.065","volume":"160","author":"C Le Berre","year":"2021","unstructured":"Le Berre, C. & Peyrin-Biroulet, L. Selecting end points for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD. Gastroenterology 160, 1452\u20131460 (2021).","journal-title":"Gastroenterology"},{"key":"1259_CR10","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/ibd\/izag022","volume":"32","author":"OM Nardone","year":"2026","unstructured":"Nardone, O. M. et al. Prevalence of disability in inflammatory bowel disease: a systematic review and meta-analysis. Inflamm. Bowel Dis. 32, 1256\u20131267 (2026).","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01259-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01259-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01259-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:18:06Z","timestamp":1788967086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01259-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":10,"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1038\/s41575-026-01259-9","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"9 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.B. has served as a speaker for AbbVie, Alfasigma, Eli Lilly, Ferring, Giuliani, Johnson & Johnson, Pharmaextracta, Pfizer and Takeda; and has served as a consultant for AbbVie, Eli Lilly and Johnson & Johnson. S.S. holds research grants from Takeda, Pfizer, Johnson & Johnson, AbbVie and Tillotts Pharma; has received consulting fees from Takeda, AbbVie, Merck, Ferring, Pharmacosmos, Warner Chilcott, Johnson & Johnson Innovative Medicine, Dr Falk Pharma, Biohit, TriGenix, Celgene and Tillotts Pharma; and payment or honoraria from AbbVie, Takeda, Celltrion, Pfizer, Biogen, Johnson & Johnson Innovative Medicine, Merck, Warner Chilcott and Dr Falk Pharma. B.G. has served as a speaker for AbbVie, Johnson & Johnson, Takeda, Roche, Gilead, Pfizer, Eli Lilly, Dr Falk Pharma, MD Education and Galapagos; and as an advisor for Roche, Johnson & Johnson, Gilead, AbbVie, MSD, Galapagos and Takeda. A.A. has received consulting or advisory board fees from AbbVie, Abivax, Alfasigma, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli Lilly, Enthera, Ferring, Galapagos, Gilead, Giuliani, Janssen, Lionhealth, Merck, Nestl\u00e9, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sanofi, Sandoz, Takeda, Teva Pharmaceuticals and Tillotts Pharma; and speaker\u2019s fees from AbbVie, Abivax, AG Pharma, Alfasigma, Biogen, Bristol-Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, Gilead, Janssen, Lionhealth, Merck, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Sanofi, Takeda and Teva Pharmaceuticals. F.M. has served as a speaker and received honoraria from Merck Sharp & Dohme, AbbVie, Vifor, Falk, Laboratorios Vitoria, Ferring, Hospira and Biogen. V.J. has received consulting and\/or advisory board fees from AbbVie, Alimentiv, Anaptyis Bio, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Endpoint Health, Enthera, Ensho, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Innomar, JAMP, Janssen, Merck, Metacrine, Mylan, MRM Health, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus Biosciences, Reistone Biopharma, Roche, Roivant, Sandoz, Second Genome, Sorriso, Spyre, Synedgen, Takeda, Teva, Ventyx, and Vividion; and speaker fees from AbbVie, Ferring, Bristol Myers Squibb, Eli Lilly, Fresenius Kabi, Janssen, Pfizer, Shire, Takeda, and Tillotts. E.V.S. has served as speaker for Abbvie, Aboca, Abivax, Agave, AGPharma, Alfasigma, Apoteca, Biosline, CaDiGroup, Celltrion, Dr Falk Pharma, EG Stada Group, Eli Lilly, Fenix Pharma, Galapagos, Giuliani, Johnson & Johnson, JB Pharmaceuticals, Innovamedica\/Adacyte, Lionhealth, Malesci, Mayoly Biohealth, Montefarco, Novartis, Omega Pharma, Pfizer, Rafa, Reckitt Benckiser, Recordati, Sandoz, Sanofi\/Regeneron, SILA, Takeda, Tillots and Unifarco; has served as consultant for Abbvie, Alfasigma, Apogee, AstraZeneca, Biogen, Bristol-Myers Squibb, Celltrion, Dr Falk Pharma, Eli Lilly, Fenix Pharma, Ferring, Giuliani, Grunenthal, Johnson & Johnson, JB Pharmaceuticals, Merck, Nestl\u00e8, Pfizer, PRO.MED.CS, Reckitt Benckiser, Recordati, Sanofi\/Regeneron, SILA, Takeda and Unifarco; and has received research support from Bonollo, Difass, Pfizer, Reckitt Benckiser, Sanofi\/Regeneron, SILA, Unifarco and Zeta Farmaceutici. A.C.F. declares no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}